{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-006974","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.722244+00:00","generated_at":"2026-06-18T08:41:12.464433+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Anebulo appoints Sandra A. Gardiner as Acting CFO via Potrero Hill Advisors agreement","bullets":["Sandra A. Gardiner appointed Acting CFO, principal financial and accounting officer effective March 2, 2023.","Gardiner replaces Rex Merchant; she will provide services through Master Services Agreement with Potrero Hill Advisors.","Gardiner previously served as CFO of Pulse Biosciences (Nasdaq: PLSE) and Cutera, Inc.","Master Services Agreement has five-year term, hourly rate compensation with annual 5% increase option, and 30-day termination notice.","No direct agreement between Company and Gardiner; all terms governed by the consulting arrangement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-006974","json":"https://secwatch.observer/filing/0001493152-23-006974.json","markdown":"https://secwatch.observer/filing/0001493152-23-006974.md","text":"https://secwatch.observer/filing/0001493152-23-006974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223006974/0001493152-23-006974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223006974/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:41:12.464433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e521e5ddd","claim":"Sandra A. Gardiner was appointed as Acting Chief Financial Officer at Anebulo Pharmaceuticals, Inc..","evidence_excerpt":"On March 2, 2023, the Company appointed Sandra A. Gardiner as the Company’s Acting Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, replacing Rex Merchant in such capacities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223006974/0001493152-23-006974-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Acting Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"cdf628d9b6","claim":"Rex Merchant departed as Chief Financial Officer at Anebulo Pharmaceuticals, Inc..","evidence_excerpt":"replacing Rex Merchant in such capacities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223006974/0001493152-23-006974-index.htm","confidence":0.75,"family_label":"Executive change","details":[{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}